Early investors of Regencell Bioscience - Spoiler:
Post# of 25562
(Total Views: 156)
Posted On: 12/14/2022 9:08:05 AM
Early investors of Regencell Bioscience - Spoiler: Individual was also early supporter of Zoom
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen >300% growth since IPO and had seen heavy sell off during period of mid June, however is seen bounced around 40% since the lows in June.
Of course one of the biggest and strongest supporter of the company share is no other than the company ) who believes in a better and brighter future for the company.
The founder and company CEO, (Mr Yat-Gai Au) in supporting of his commitment, confidence and his position towards the company, he has deployed over $5 million dollars of his own personnel reserves in buying back company stock to reposition against possible short and distort sellers.
Another prominent early investor of RGC is Mr Samuel Chen, who is a very succesful early **Zoom Video Communications, Inc.** investor (Nasdaq: Zoom). Mr Samuel owned 8.8% of Zoom shares and was the second largest individual investor.
To date, Mr. Au has converted his shareholders’ loan of $3.25 million to Regencell’s ordinary shares upon listing and has pledged not to draw a salary and bonus of more than $1 until Regencell reaches a $1 billion market capitalization and reserved share options for all employees except himself.
In addition, in demonstrating the management’s commitment towards the company, all all directors and employees who were previously granted stock options upon Regencell’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i](https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i)
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen >300% growth since IPO and had seen heavy sell off during period of mid June, however is seen bounced around 40% since the lows in June.
Of course one of the biggest and strongest supporter of the company share is no other than the company ) who believes in a better and brighter future for the company.
The founder and company CEO, (Mr Yat-Gai Au) in supporting of his commitment, confidence and his position towards the company, he has deployed over $5 million dollars of his own personnel reserves in buying back company stock to reposition against possible short and distort sellers.
Another prominent early investor of RGC is Mr Samuel Chen, who is a very succesful early **Zoom Video Communications, Inc.** investor (Nasdaq: Zoom). Mr Samuel owned 8.8% of Zoom shares and was the second largest individual investor.
To date, Mr. Au has converted his shareholders’ loan of $3.25 million to Regencell’s ordinary shares upon listing and has pledged not to draw a salary and bonus of more than $1 until Regencell reaches a $1 billion market capitalization and reserved share options for all employees except himself.
In addition, in demonstrating the management’s commitment towards the company, all all directors and employees who were previously granted stock options upon Regencell’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i](https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i)
(0)
(0)